Holen Sie sich die Stockscreener-App
61.05
2.52%
1.505
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DXCM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$59.55
Offen:
$62.22
24-Stunden-Volumen:
8.04M
Relative Volume:
1.78
Marktkapitalisierung:
$23.57B
Einnahmen:
$4.66B
Nettoeinkommen (Verlust:
$836.30M
KGV:
29.17
EPS:
2.093
Netto-Cashflow:
$1.08B
1W Leistung:
-0.84%
1M Leistung:
-2.12%
6M Leistung:
+4.86%
1J Leistung:
-13.11%
1-Tages-Spanne:
$59.70
$62.80
1-Wochen-Bereich:
$56.72
$62.80
52-Wochen-Spanne:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Firmenname
Dexcom Inc
Sektor
Branche
Telefon
(858) 200-0200
Adresse
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
61.09 | 22.89B | 4.66B | 836.30M | 1.08B | 2.093 |
ABT
Abbott Laboratories
|
90.06 | 163.10B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
299.78 | 123.10B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
80.61 | 105.15B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
56.95 | 86.87B | 20.62B | 3.56B | 3.66B | 2.3847 |
EW
Edwards Lifesciences Corp
|
84.40 | 47.44B | 6.30B | 1.07B | 1.34B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-24 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2026-01-12 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Eingeleitet | Evercore ISI | In-line |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Eingeleitet | Argus | Buy |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-03 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-03-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2023-01-26 | Eingeleitet | Wolfe Research | Outperform |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-15 | Eingeleitet | Bernstein | Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-28 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-01-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-02 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Bestätigt | Piper Sandler | Overweight |
| 2020-05-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-11-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-10-23 | Eingeleitet | Stifel | Buy |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-09-12 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Bestätigt | Canaccord Genuity | Buy |
| 2018-07-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
| 2018-05-03 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-04 | Eingeleitet | Goldman | Sell |
| 2018-04-04 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Dexcom Inc Aktie (DXCM) Neueste Nachrichten
JPMorgan Adjusts DexCom Price Target to $65 From $75 - marketscreener.com
DexCom Stock Up on Q1 Earnings & Revenues Beat, Margins Rise - TradingView
DexCom, Inc. (NASDAQ:DXCM) Q1 2026 Earnings Call Transcript - Insider Monkey
Dexcom reports 15% YoY revenue uptick in Q1 yet maintains prior FY26 outlook - Yahoo Finance
DexCom Inc (NASDAQ:DXCM): A GARP Stock with Affordable Growth and Strong Fundamentals - ChartMill
Barclays Adjusts Price Target on DexCom to $67 From $72, Maintains Underweight Rating - marketscreener.com
Bernstein Adjusts Price Target on DexCom to $77 From $83, Maintains Outperform Rating - marketscreener.com
Bernstein SocGen lowers DexCom stock price target on valuation By Investing.com - Investing.com Canada
Raymond James Adjusts Price Target on DexCom to $81 From $83, Maintains Strong Buy Rating - marketscreener.com
Goldman Sachs Adjusts Price Target on DexCom to $80 From $82, Maintains Buy Rating - marketscreener.com
TD Cowen Adjusts Price Target on DexCom to $75 From $84, Maintains Buy Rating - marketscreener.com
BTIG Remains Bullish on DexCom, Inc. (DXCM) - Insider Monkey
DexCom Inc (DXCM) Q1 2026 Earnings Call Highlights: Strong Reven - GuruFocus
DexCom Inc (DXCM) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Market Expansions - GuruFocus
DexCom Q1 2026 slides: margin expansion accelerates, guidance raised By Investing.com - Investing.com South Africa
DexCom (DXCM) Reports Strong Q1 2026 Revenue Growth Driven by Pr - GuruFocus
Is It Too Late to Buy DexCom Inc (DXCM) After 3.5% Rally? GF Val - GuruFocus
DexCom (DXCM) Q1 2026 Earnings Transcript - The Motley Fool
DexCom Q1 Earnings Call Highlights - Yahoo Finance
Is DexCom (DXCM) 45.7% Undervalued After Q1 2026 Earnings Beat? - GuruFocus
Earnings call transcript: DexCom beats Q1 2026 forecasts, stock rises - Investing.com
Transcript : DexCom, Inc., Q1 2026 Earnings Call, Apr 30, 2026 - marketscreener.com
DexCom Q1 2026 Earnings Call Transcript - Benzinga
DexCom, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
DexCom (DXCM) Q1 Earnings and Revenues Top Estimates - Yahoo! Finance Canada
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
Dexcom reaffirms full-year forecast after topping quarterly estimates - marketscreener.com
Dexcom shares fell as it reaffirms full-year outlook By Investing.com - Investing.com Canada
DexCom (NASDAQ:DXCM) Beats Q1 Earnings Forecasts, But Guidance and Revenue Miss Fuel After-Hours Drop - ChartMill
Dexcom falls over 5% despite better-than-expected Q1 print, as revenue guidance disappoints - Investing.com India
Q1 2026 Dexcom Inc Earnings Call Transcript - GuruFocus
DexCom Q1 Adjusted Earnings, Revenue Rise - marketscreener.com
DexCom (NASDAQ:DXCM) Exceeds Q1 CY2026 Expectations But Stock Drops - Yahoo Finance
Earnings Flash (DXCM) DexCom, Inc. Reports Q1 Revenue $1.19B, vs. FactSet Est of $1.17B - marketscreener.com
Earnings Flash (DXCM) DexCom, Inc. Posts Q1 Adjusted EPS $0.56 per Share, vs. FactSet Est of $0.47 - marketscreener.com
DexCom: Q1 Earnings Snapshot - KTVB
[8-K] DEXCOM INC Reports Material Event - Stock Titan
DexCom earnings ahead: Can margin gains offset growth concerns? By Investing.com - Investing.com South Africa
DexCom earnings ahead: Can margin gains offset growth concerns? - Investing.com
Dexcom Inc. Stock (US2521311074): Q1 2026 Earnings Release Scheduled for April 30 - AD HOC NEWS
Is DexCom’s (DXCM) G7 Sensor Upgrade Quietly Redefining Its Core Recurring-Revenue Story? - simplywall.st
Vanguard Capital Management (NASDAQ: DXCM) reports 7.49% ownership - Stock Titan
DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Vanguard discloses 19.3M Dexcom shares as 5.02% holding (NASDAQ: DXCM) - Stock Titan
DexCom (DXCM) Q1 Earnings: What To Expect - Yahoo Finance
Why Medtech Giants Are Quietly Paying Up for AI Diagnostics - Benzinga
Why DexCom (DXCM) is a Top Value Stock for the Long-Term - Yahoo Finance
A Look at DexCom Inc (DXCM) After 3.4% Decline -- GF Value $109. - GuruFocus
DexCom (DXCM) Q1 earnings: What to expect - MSN
DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Rick Osterloh Joins Dexcom’s Board of Directors - Medical Product Outsourcing
Finanzdaten der Dexcom Inc-Aktie (DXCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.17%
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):